1-4 of 4
Michelle Blaskovich
Close
Sort by
Journal Articles

Expansion and Characterization of Iovance Marrow Infiltrating Lymphocytes: A Potential Novel Therapeutic Strategy for the Treatment of Acute Myeloid Leukemia

Lavakumar Karyampudi, PhD, Ian Frank, Michelle Blaskovich, John C. Byrd, MD, Cecile Chartier, Meixiao Long, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5683.
https://doi.org/10.1182/blood-2018-99-114825
Published: 2018
Journal Articles

A Phase 1 Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias.

Jeffrey E. Lancet, MD, Elliott F. Winton, MD, Robert K. Stuart, MD, Michelle Burton, RN, Christopher Cubitt, PhD, Michelle Blaskovich, John Wright, MD, PhD, Said Sebti, PhD, Daniel Sullivan, MD, MS
Journal: Blood
Blood (2008) 112 (11): 1945.
https://doi.org/10.1182/blood.V112.11.1945.1945
Published: 2008
Journal Articles

First Clinical Report of Tipifarnib for the Treatment of T-Large Granular Lymphocyte (LGL) Leukemia.

P.K. Epling-Burnette, PhD, Lubomir Sokol, MD, Lynn Moscinski, MD, Magda Elkabani, MD, Fanqi Bai, MD, Michelle Blaskovich, BS, JianXiang Zou, MD, Jeffrey S. Painter, BS, Said Sebti, PhD, Thomas P. Loughran, MD
Journal: Blood
Blood (2007) 110 (11): 3132.
https://doi.org/10.1182/blood.V110.11.3132.3132
Published: 2007
Journal Articles

Th2 Polarization Induced by the Farnesyltransferase Inhibitor Tipifarnib (Zarnestra®, R115777) through Suppression of T-bet.

Fanqi Bai, MD, J.-X. Zou, MD, Sheng Wei, MD, Jeffrey S. Painter, BS, Michelle Blaskovich, Bs, Said Sebti, PhD, Thomas P. Loughran, MD, P.K. Epling-Burnette, PhD
Journal: Blood
Blood (2007) 110 (11): 1331.
https://doi.org/10.1182/blood.V110.11.1331.1331
Published: 2007